Zobrazeno 1 - 10
of 21 823
pro vyhledávání: '"Chronic Myelogenous Leukemia"'
Publikováno v:
BMC Ophthalmology, Vol 24, Iss 1, Pp 1-5 (2024)
Abstract Background Chronic myeloid leukemia (CML) can manifest ocular complications stemming from hematologic irregularities or direct infiltration of neoplastic cells. This article details the case of a patient with newly diagnosed CML exhibiting e
Externí odkaz:
https://doaj.org/article/1cc26ebb9a4349f98fb26d4cdeec39fa
Autor:
Mahdi Edalati, Shaban Alizadeh, Asghar Abdoli, Forouzan Karam, Aliakbar Shekarchi, Mahtab Sayadi
Publikováno v:
مجله دانشگاه علوم پزشکی بیرجند, Vol 31, Iss 1, Pp 79-90 (2024)
Background and Aims: According to the increasing evidence, abnormal expression of microRNAs is associated with tumorigenesis, tumor spread, and relapse in leukemias, including chronic myeloid leukemia (CML). The present study aimed to investigate the
Externí odkaz:
https://doaj.org/article/8a9fdcdf101a48ea8ef06f380f50c3ae
Autor:
D.V. Dobrianskyi, G.L. Gumeniuk, P.F. Dudka, I.P. Tarchenko, Т.І. Коzаr, А.V. Кuchаrskа, Т.А. Leonova
Publikováno v:
Infusion & Chemotherapy, Iss 1, Pp 44-50 (2024)
ABSTRACT. Leukemoid reaction (LR) is a transient hematological syndrome of reactive nature characterized by persistent leukocytosis of more than 50,000 cells/µL. LR can be caused by a variety of factors, including infections, intoxications, malignan
Externí odkaz:
https://doaj.org/article/cca4782229d54a56b43592b290721a25
Autor:
Yi-gang Guo, Lu-lu Zhang, Ping Hu, Zhang-zhi Li, Rui-bo Zhang, Xi Lv, Qiong Yi, Ling-bo Zhan, Xue-lian Feng
Publikováno v:
Hematology, Vol 29, Iss 1 (2024)
ABSTRACTObjective: This study analyzed the relationship between bone marrow microvessel density (MVD) and the expression of four miRNAs with chronic myelogenous leukemia (CML) resistance after tyrosine kinase inhibitor (TKI) treatment.Methods: 234 CM
Externí odkaz:
https://doaj.org/article/5f2ead28828a425d9fe5e06fdd417370
Autor:
Naoki Okamoto, Kenta Yagi, Sayaka Imawaka, Mayu Takaoka, Fuka Aizawa, Takahiro Niimura, Mitsuhiro Goda, Koji Miyata, Kei Kawada, Yuki Izawa‐Ishizawa, Satoshi Sakaguchi, Keisuke Ishizawa
Publikováno v:
Pharmacology Research & Perspectives, Vol 12, Iss 4, Pp n/a-n/a (2024)
Abstract In the treatment of chronic myeloid leukemia (CML), resistance to BCR‐ABL inhibitors makes it difficult to continue treatment and is directly related to life expectancy. Therefore, asciminib was introduced to the market as a useful drug fo
Externí odkaz:
https://doaj.org/article/eef81c91c9db4fafb2a4727bbd78f2ae
Autor:
Phatchanat Klaihmon, Chanchao Lorthongpanich, Pakpoom Kheolamai, Wannachai Saisaard, Surapol Issaragrisil
Publikováno v:
Scientific Reports, Vol 14, Iss 1, Pp 1-10 (2024)
Abstract Chronic myelogenous leukemia (CML) is a clonal hematologic malignancy of the myeloid lineage caused by the oncogenic BCR/ABL fusion protein that promotes CML cell proliferation and protects them against drug-induced apoptosis. In this study,
Externí odkaz:
https://doaj.org/article/3e7762c9992a488c9ff56dd679a37ade
Autor:
Max Robles-Nasta, Daniela Sánchez-Bonilla, Moises M. Gallardo-Pérez, Edgar J. Hernández-Flores, Merittzel A. Montes-Robles, María de L. Pastelín-Martínez, Juan C. Olivares-Gazca, Guillermo J. Ruiz-Delgado, Guillermo J. Ruiz-Argüelles
Publikováno v:
Revista de Investigación Clínica, Vol 76, Iss 2 (2024)
Background: Chronic myelogenous leukemia is a neoplastic proliferation of the granulocytic series. In Mexico, chronic myelogenous leukemia accounts for approximately 10% of all leukemias. Tyrosine-kinase inhibitors are considered front-line therapy i
Externí odkaz:
https://doaj.org/article/8a1fc4cbe7734a1eb3630b5eae574bf0
Autor:
Johannes Paladini, Annalena Maier, Judith Maria Habazettl, Ines Hertel, Rajesh Sonti, Stephan Grzesiek
Publikováno v:
eLife, Vol 12 (2024)
Abelson tyrosine kinase (Abl) is regulated by the arrangement of its regulatory core, consisting sequentially of the SH3, SH2, and kinase (KD) domains, where an assembled or disassembled core corresponds to low or high kinase activity, respectively.
Externí odkaz:
https://doaj.org/article/ef746d7d048644ea99ceb28b7e3f3eec
Autor:
Robert Roskoski, Jr.
Publikováno v:
Pharmacological Research, Vol 200, Iss , Pp 107059- (2024)
Owing to the dysregulation of protein kinase activity in many diseases including cancer, this enzyme family has become one of the most important drug targets in the 21st century. There are 80 FDA-approved therapeutic agents that target about two doze
Externí odkaz:
https://doaj.org/article/37a596467db74f7cab452973739ae8d5
Autor:
Xuxiu Lu, Fengli Yuan, Liang Qiao, Yankai Liu, Qianqun Gu, Xin Qi, Jing Li, Dehai Li, Ming Liu
Publikováno v:
Biomedicine & Pharmacotherapy, Vol 171, Iss , Pp 116099- (2024)
Chronic myelogenous leukemia (CML) is characterized by the constitutive activation of BCR-ABL tyrosine kinase. Imatinib was approved for CML therapy, however, BCR-ABL-dependent drug resistance, especially BCR-ABL-T315I mutation, restricts its clinica
Externí odkaz:
https://doaj.org/article/a8b9fde1598844f3b1be00692991224c